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Heterogeneity of Pemphigoid Antigens 
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The immunologic specificity of bullous pemphigoid 
(BP) antigens expressed in human skin was studied by 
reacting the sera of 34 pl;ltients with BP with several 
specimens of normal skin. Most sera with basement 
membrane zone (BMZ) antibodies reacted to antigens 
expressed in all specimens of skin examined. A minority 
of pemphigoid sera reacted to BP antigens expressed in 
some specimens of skin but not in others. The pattern of 
cross-reactivity suggests that BP antigens are hetero-
geneous and that two different groups can be defined 
serologically. The first is a universal BP antigen(s) which 
is expressed in all individuals and to which antibodies 
are formed in most patients with BP. The other group 
consists of a family of BP antigens whose expression 
varies from individual to individual. Several immunolog-
ically distinct BP antigens can be expressed concur-
rently in the same specimen of skin. Lastly, the apparent 
absence of BMZ antibodies in some patients with BP is 
occasionally the result of antibodies directed to "minor" 
BP antigens wj.th restricted expression. 
Bullous pemphigoid (BP) antigen is a normal component of 
the basement membrane zone (BMZ) of human skin. The 
antigen is defined serologically using antibodies present in the 
serum of patients with BP. BP antigen is tissue-specific [1,2], is 
expressed by keratinocytes in tissue culture [3,4], is synthesized 
by epidermal basal cells [4,5], and disappears in more differen-
tiated keratinocytes [6]. BP antigen is of considerable interest 
because of its involvement in the pathogenesis of BP [7,8], and 
because it is a marker of epidermal cell differentiation [9,10]. 
As a result, a number of efforts have been made to characterize 
BP antigen, with widely diverging results. BP antigen has been 
extracted from human epithelia, urine, saliva, and keratinocytes 
grown in vitro, but its molecular weight (Mr) has been reported 
as ranging from 20 to 220K [11-13]. It is unclear whether these 
variations are a result of extraction procedures altering the 
properties of the antigen, whether limited immunologic speci-
ficity studies have resulted in the erroneous designation of an 
unrelated epidermal product as BP antigen, or whether there 
exist multiple BP antigens in the BMZ. There is some evidence 
to suggest that the latter may be true. Antibodies in sera of 
patients with BP may stain antigens expressed in the epidermal 
BMZ of some mammals but not of others [14], suggesting that 
BP antigens of different immunologic specificities are present 
in different species. Whether different BP antigens are ex-
pressed in humans, and whether this could account f01" the 
heterogeneity in the antigens described to date, is presently 
unknown. 
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In the following study we have examined the immunologic 
specificity of BP antigens expressed in normal human skin. Our 
findings suggest that several antigens reactive wi"th sera of 
patients with BP are present in normal human skin, that these 
antigens differ in their immunologic specificity, and that they 
are expressed to different degrees in different individuals. 
MATERIALS AND METHODS 
Sera 
Sera were collected from 34 patients with BP. The disease was 
confirmed histologically in all cases. Twenty-four sera had antibodies 
to BP antigens in tite,rs greater than 1/640 when tested aganst monkey 
and guinea pig esophagus by indirect immunofluorescence in an initial 
routine assay. Of these, 16 also reacted to the single specimen of human 
skin used in the assay. The remaining 10 sera did not have detectable 
BMZ antibodies against monkey or guinea pig esophagus or human 
skin in an initial assay. All 10 of these patients had linear deposits of Ig 
and/or C'3 at the BMZ on direct immunofluorescence. In addition, sera 
from 2 normal individuals without blistering diseases were used as 
controls. Sera were stored at -30°C until use. 
Substrate 
Normal human skin was obtained by punch biopsy or excision from 
10 individuals. The specimens were immediately frozen in liquid nitro-
gen and stored for no longer than 7 days at -30°C. For use, the tissues 
were embedded in OCT compound (TissueTek, Ames Co., Elkhart, 
Illinois) and cut in 4-llrn sections on a cryostat. 
Conjugates 
Fluorescein-labeled goat antihuman IgG serum was purchased from 
Hyland Co. (Costa Mesa, California) . It reacted specifically to human 
IgG by immunoelectrophoresis. The protein concentration was 24 mg/ 
ml, the antibody content 1.6 mg/ ml, the fluorescein isothiocyanate 
concentration 2.166 mg/ ml, and the fluorescein to protein ratio 6.0 mg/ 
gm. For use, the conjugate was diluted 1/ 50 in phosphate buffered 
saline. 
Immunofluorescence Tests 
Indirect immunofluorescent tests were performed by standard tech-
niques as previously described [15]. All sera were tested at dilutions of 
1/20 and 1/40, and to exclude negative reactions due to prozone 
phenomena at dilutions of 1/320 and 1/1280. Slides were read with a 
Zeiss binocular microscope equipped with an HBO 200 mercury vapor 
lamp and Zeiss FITC exciter and "50" barrier filters. All tests were 
done in duplicate and all sLides were read blindly by 2 observers. Similar 
results were obtained in all instances. 
The immunofluorescence tests were performed in 3 phases. In the 
first phase, the results of which are shown in Tables I and III, the 16 
sera with BMZ antibodies reactive to monkey and guinea pig esophagus 
and to human skin in the initial screen and 2 normal human sem were 
tested with 5 specimens of normal allogeneic skin. In the second phase, 
the results of which are shown in Table II, an additional 8 sera with 
BMZ antibodies reactive to monkey and guinea pig esophagus but not 
to human skin in the initial screen were reacted against 3 of the skin 
specimens used in the first phase. In the last phase, the results of which 
are shown in Table IV, 10 sera of patients with BP but without 
detectable BMZ antibodies to monkey or guinea pig esophagus or 
human skin in the initial screen, were reacted against 5 new specimens 
of normal allogeneic skin. 
RESULTS 
Expression of Pemphigoid Antigen in Human Skin 
To study the expression ofBP antigen in different individuals, 
a panel of sera from 16 patients with BP and 2 normal individ-
uals was reacted with 5 specimens of normal allogeneic skin. 
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TA BLE I. Expression of p emp h ig oid antigens in different 
individual:; 
Pemphigoid 
Reaction Lo BM Z antigens" 
serum no. S kin specimen 
A B C 0 E 
1 + + + + NT" 
2 + + + + + 
3 + + + + + 
4 + + + + + 
5 + + + + 
6 + + + + + 
7 + + + + + 
8 + + + + + 
9 + + + + + 
10 + + + + + 
11 + + + + + 
12 + + + 
13 + + + + 
14 + + + + 
15 + + + + 
16 + + + + + 
" By indirect immunoflu orescence. Sera were tested at 1:40, 1:320, 
and 1:1280. 
" NT = not tested. 
The pemphigoid sera were selected on the basis of their reacting 
to monkey and guinea pig esophagus as well as to a single 
specimen of human skin in an initial screen. The results ar e 
summarized in T able I. Most (68.7%) sera reacted to antigens 
expressed in all 5 specimens of skin . However some sera had 
antibodies that reacted to BMZ antigens ex~ressed in some 
specimens of skin bu t not to others. Thus, serum 13 reacted to 
skin specimens A, B, D, and E, but not to C (see Fig. lA,B) . 
Conversely, serum 12 reacted to specimens C as well as A and 
E, but not to specimens B and D (see Fig 1C,D). T he possibili ty 
that the variation in reactivity resul ted from changes in tissue 
concentration of a single antigen was considered but thought to 
be unlikely for the reason that there was no consistency in the 
pattern of negative and positive reactions. T issues unJ'eactive 
to one serum were not consistently negative to other sera as 
would be the case if lack of reactivity were due to decreased 
tissue concentration of an antigen. Conversely, sera reactive 
with one skin specimen did not consistently give positive reac-
tions with other specimens as would be the case ifthe variations 
resulted from differences in the ti ters or affini ty of BMZ anti-
bodies. Masking of antigenic sites on a single BP antigen 
molecule was also considered as a cause for the variation in 
reactivity. However, this is unlikely since skin specimens un-
reactive with antibody from one individual with BP could react 
with antibodies fTom another patient with the same disease, 
indicating the antigenic site was not blocked. None of the 
antibodies in this 01' subsequent s tudies reacted with other 
epiderma-l; dermal, or vascular components in skin, indicating 
they were not directed to laminin, fibro nectin, or type IV 
collagen which are all expressed in other dermal structUJ·es. Nor 
did any of the antibodies react to a number of non epithelial 
cells present in skin such as fibroblasts, lymphoid or endothelial 
cells. These observations suggest that BMZ an tibodies in BP 
aTe directed to a group of BP antigens that differ in their 
immunologic specificity as well as in their expression in different 
individuals. 
T o confirm that BP antigens are heterogeneous, the above 
studies were repeated using a new panel of BP sera. T o maxi-
mize the chances of detecting BP antigen heterogeneity, the 
sera were selected on the basis of their having high titers (above 
640) of antibodies to BMZ ant igens in monkey and guinea pig 
esophagus bu t no detectable reaction to a single specimen of 
human skin in an initial screen. The results are summarized in 
T able II. Seven of 8 pemphigoid sera examined had antibodies 
to BP antigens in human skin when tested against 3 new 
specimens of skin . In most instances the titer of the antibodies 
was low. However, in 2 (25%) of the sera, BMZ antibodies were 
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present in titers of 320 0 1' gI·eater. As noted previously, but to 
a more striking extent, the presence of positive reactions dif-
fered depending on the serum and skin specimen used. Three 
of the 8 sera reacted to BMZ antigens present in all 3 specinlens 
of skin. On the basis of cross-reactivity patterns the remaining 
pemphigoid sera appeared to be dU'ected to several other BP 
antigens with more limited expression. T hus, one BP antigen, 
reactive with sera 18 and 23 was present in skin specimen B 
and C whereas a second BP antigen reactive with sera 19 was 
only present in skin specimen B. The resul ts of these studies 
confu'm that BP antigens differ both in theu' unmunologic 
specificity and in theu' expression in different individuals. 
T o study wheth er the expression of BP antigens in h uman 
skin was an all-or-none phenomenon, their amount was esti-
mated from the highest dilu tion of pemphigoid sera capable of 
staining the BMZ. The skin and sera specimens studied were 
those used in the fU'st experiment described above. The results 
are summarized in Table III. In the majority of instances there 
were differences in titer when the same serum was reacted with 
several specunens of allogeneic skin. For example, the titer of 
sera 13 was 1280 when tested against skin specimens A and E, 
320 when tested against Band D, and zero when tested against 
C. All 16 pemphigoid sera studied showed sinl ilar variations in 
the intensity of BMZ staining with different specimens of skin. 
This observation suggests that the expression of BP antigens is 
not an all-or-none phenomenon bu t rather fluctuates in differ-
ent individuals. 
R eaction of BMZ A ntibody N egative Pemphigoid Sera to 
Human Shin 
A number of studies indicate that approximately 10-30% of 
patients with BP lack BMZ antibodies [16,17]. As is comm on 
practice, the indu'ect immunofluorescence tests for pemphigoid 
antibodies in these studies were performed using monkey or 
guinea pig esophagus as substrate. Since our observations in-
dicate that there are a number of different pemphigoid antigens, 
we considered the possibility that the apparent absence of BMZ 
antibodies in some pemphigoid patients resulted from anti-
bodies directed to BP ant igens present only in human skin. To 
study this question, 10 sera obtained from patients with biopsy-
proved BP but negative for BMZ ant ibodies to monkey and 
guinea pig esophagus were tested against 5 new specimens of 
normal human skin. All 5 specimens of skin were shown in 
preliminary studies to express BP antigens reactive with sera of 
2 patients with BP who had BMZ antibodies to universally 
expressed BMZ antigens. The results are summarized in Table 
IV. One serum reacted to BP antigens in human skin. T he titer 
of the reaction was low [20]. The serum reacted to 4 of 5 skin 
specinlens. This finding indicates that in a limited number of 
instances the apparent absence of BP antibodies in patients 
with BP results from antibodies being dU'ected to BP antigens 
with restricted expression. 
DISCUSSION 
The findings of this study suggest that there is a heteroge-
neous population of BP antigens. BP antigens with different 
immunologic specificity may be present concUl'rently in the 
same specimen of skin . Both the type and the amount of 
individual BP antigens expressed in Skill may vary from person 
to person. In the majority of instances, patients with BP develop 
antibodies to major BP antigen(s) which are expressed in the 
epidermis of most individuals. However, some pemphigoid anti-
bodies ar e dU'ected to minor BP antigens with more limited 
distribut ion. 
Linear deposits of immunoglobulin are present at the BMZ 
in skin lesions of BP [18] and most pa tients with this disease 
have circulating antibodies directed to BMZ antigens [1]. The 
antigen in question is t issue- but not species-specific [2] and is 
located at a site that corresponds exactly to that of the earliest 
lesion of the disease that can be visualized by electron micros-
copy [1,19]. As a resul t ofthese observations it is widely believed 
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that pemphigoid is an autoimmune disease involving antibodies 
to a normal component of the BMZ of skin caJl ed the pemphi-
goid antigen. Several attempts have been made to characterize 
the BP antigen with widely different results. The apparent M,. 
of BP antigen extracted from human skin and urine by Diaz et 
al [11 , 12] was 20K on SDS-PAGE, whereas that purified from 
cultured human keratinocytes by Stanley et a l was 220K [13). 
BP antigens have also been described as soluble [13) and 
insoluble [20] in nonionic detergents. The results of our study 
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FI G. 1. Indirect immunofluorescence 
photomicrograph of immunologically 
distinct BP antigens. Antibodies in BP 
serum 13 react with BP a nt igens ex-
pressed in human skin specimen B (a), 
but not in skin specimen C (b). By con-
trast, the BP antigens recognized by BP 
serum 12 al 'e not expressed in s kin spec-
imen B (c) but are expressed in skin 
specimen C (d). Original magnification 
X 312. 
suggest that one explanation for these differences is tha t there 
are several BP antigens and that these can vary in their distri-
bution among different individuals and from species to species. 
We examined the specificity and distribu tion of BP antigens 
to which antibodies al'e present in patients with BP by reac ting 
a panel of sera from patients with the disease with several 
specimens of allogeneic skin. The resul ts indicate that there is 
a heterogeneous population of immunologically distinct BP 
antigens. Two groups of BP antigens can be defined serologi-
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TABLE II. R eaction of pemphigoid sera unreactive to humall shin, 
in an initial screen to an expanded panel of human shin 
Pemphigoid 
Ti te r ofl'c.nclion Lo BMZ a ntigens" 
serum no. Skill :-;pec imen 
B C 0 
17 20 0 0 
18 40 40 0 
19 0 40 0 
20 ;.120 320 40 
21 40 40 20 
22 1280 1280 40 
23 40 20 0 
24 0 0 0 
"By indirect immunoflu orescence. Scra were tested at 1:20, 1:40, 
1:320, a nd 1:1 280. 
TABl.E Ill. Quantitative expression of BP antigens ,:n d ifFerent 
individuals 
Tile r o f reac t ion to 8MZ ant ige ns" 
Pemphigoid 
serum no. Sk in specimen 
A B C 0 E 
;.120 40 40 40 NT" 
2 1280 1280 1280 320 1280 
3 1280 1280 1280 1280 ::120 
4 1280 320 ;.120 40 ::120 
5 1280 320 l280 320 0 
6 1280 1280 1280 320 1280 
7 1280 320 1280 320 1280 
8 1280 320 1280 1280 320 
9 :320 40 40 40 40 
10 1280 320 ;.120 320 ::120 
II 1280 40 ;.120 40 320 
12 ;.120 0 40 0 40 
13 1280 ;.120 0 320 1280 
14 40 320 0 40 320 
15 ::120 ;.120 0 40 320 
16 40 ;.120 40 40 320 
" By indirect immunofluorescence. Sera we re tesled at 1 :40, 1:;320, 
1:1 280. 
" NT = not. les ted. 
TABLI, IV. R eacliun 10 human shin a/pemphigoid sern ullreacli ve 
10 lII olI/,'ey and Nllill ea pig esophaglls 
Pemphigoid 
serum no. 
25 
26 
27 
28 
29 
30 
3J 
32 
33 
34 
3" 
7" 
Monl,c y 
e~ophag·u s 
+ 
+ 
Bcaclion to BMZ alll il:C IlH" 
Guinea pig 
esu pllabus 
+ 
+ 
Skin spec imen 
F G H 1 ./ 
+ + + + 
+ + + + + 
+ + + + + 
"By indirect immunoflu orescence. Sera lesled at. 1 :20, 1 :40 , and 
1:320. 
" Posit ive control sera wilh B MZ a ntibod ies. 
cally. One group consists of antigen(s) which is universally 
expressed in all individuals within the limi ts of the serologic 
studies performed. This is evidenced by antibodies that react 
with equal strength to BMZ antigens in all skin specimens 
examined. Whether one or several different antigens are present 
in this group cannot be resolved by these stuclies. However, t he 
recent observations of Stanley et al [13] that the antigen 
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recognized by several different BP sera all had the same M r , 
suggest that there is only a single antigen. The other group of 
BP antigens consists of antigens which are expressed in some 
but not all individuals. There appears to be a family of such 
antigens that are expressed variably and with overlapping dis-
tribution in different individuals. These antigens are demon-
strated by vaj'ying cross-reaction patterns obtained when pem-
phigoid sera ar e reacted with skin from different persons. Both 
types of BP antigens can be expressed concurrently in normal 
human skin. None of the BP antigens appears to be related to 
other normal components of the BMZ, such as laminin [21], 
fibronectin [22], or type IV collagen [23]. These components 
are expressed in other dermal structures such as blood vessels 
[24] which were not stained by any of the sera used. Nor do 
any other BP antigens appeal' to be expressed in nonepidermal 
t issues present in skin, such as fibroblasts or endothelial or 
lymphoid cells, since these were not stained by any of the sera 
used. Whether some of the variably expressed BP ant igens are 
present in other nonepidermal tissues is not presently known. 
The results of our experiments also suggest that the BMZ 
antibodies in patients with BP are heterogeneous, since they 
may be directed to different antigens. It is fortunate from a 
diagnostic viewpoint t hat the BMZ antibodies in most individ-
uals with BP aj'e directed to the universal group of BP anti-
gen(s). The practical implication of this finding is that in the 
majority of cases BP antibodies will be detected regardless of 
the stratified squamous epithelium that is used as a substrate. 
In the remaining patients, pemphigoid antibodies are directed 
to BP antigens whose distribution varies from person to person. 
This phenomenon may account to a limited extent for the 
appar ent absence of BMZ antibodies in 20- 30% of patients with 
BP. In this study, of 10 patients with pemphigoid and absent 
BMZ antibodies by conventional immunofluorescence assays 
using monkey and guinea pig esophagus as substrates, I (10%) 
had BMZ antibodies reactive only to human skin . 
The amount of BP antigens present in skin was estimated 
from the highest dilu tion of BMZ antibodies that still gave 
positive staining. The results are admittedly only semiquanti-
tative. However, they suggest that the expression ofBP an tigens 
is not an all-or-none phenomenon but rather that it fluctuates 
from individual to individual. Because absorption studies could 
not be performed, we were unable to completely exclude the 
possibility that some of the flu ctuation in staining results from 
the presence of antibodies to multiple BMZ antigens in the 
same specimen of skin, t he expression of each of which flu c-
tuates in an aJl-or-none manner. 
There ar e several implications to these findings . It is evident 
that to maximally increase the sensitivity of indirect immuno-
fluorescence assays for BMZ antibodies in patients with BP, 
the assays should be performed on multiple substrates including 
human skin. Negative results in patients suspected of having 
this disease should be repeated using additional substrates. It 
is also evident that because the type and amoun t of BMZ 
antigens may fluctuate from substrate to substrate, even if fro m 
the same species, seria l determination of BMZ antibody titers 
over prolonged periods of time may be inaccurate. Conse-
quently, the poor correlation noted in many studies between 
titer of BMZ antibodies and clinical activity of BP [25] may be 
artifactual rather than real. Accurate determination of serial 
antibody titers requires that all assays be performed on the 
same substrate. The presence of immunologically distinct BP 
antigens in skin may be paralleled by heterogeneity in the 
biochemical properties of these antigens. This may account in 
part for the varying biochemical proper ties that have been 
ascribed to pemphigoid antigens. Lastly, it is tempting to spec-
ulate that the presence of BMZ antibodies directed toward 
different BP antigens in different individuals with BP may play 
a role in the varying clinical manifestations of this disease. 
'rhe excellent technical assistance of Ms. Anna Rohoza and Mr. 
Michael Sabolinski are grat.efully acknowledged. 
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Glycoprotein Composition of Psoriatic Epidermis in Relation to Growth 
Control 
HENK ROELFZEMA, PH.D. AND PIET E. J. VAN ERP 
Department of Dermatology, University of Nijmegen, Nijmegen, The Netherlands 
The composition of isolated ["H]-fucose- and ["H]-glu-
cos amine-labeled glycopeptides from psoriatic lesion, 
psoriatic uninvolved, regenerating-normal, and normal 
epidermis (subdivided into basal and differentiated cells) 
has been analyzed according to molecular weight and 
affinity to concanavalin A. Basal cells from normal skin 
have a higher sialic acid content of their "biantennary" 
fucose-labeled glycoprotein!'; than differ entiated cells . 
Manuscript received November 16, 1981; accepted for publication 
April 26, 1982. 
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ogy, Philips van Leyden laan 25, 6525 Nijmegen, The Netherlands. 
Abbreviations: 
a- MM: a-methy[-D-mannoside 
Con-A: concanavalin A 
TCA: trichloroacetic acid 
Fucose-labeled glycoproteins from regenerating norma l 
skin show an increased molecular weight of their car-
bohydrate moieties which precedes entrance of the cell 
into S-phase. In psoriatic uninvolved skin, glycoproteins 
with more highly branched carbohydrate structures are 
present in reduced quantity. The previously reported 
increase in percentage of high-molecular-weight fucose-
labeled glycopeptides for psoriatic lesions appears to be 
specific in that its composition cannot be explained in 
terms of an increased growth fraction. 
Striking abnormalities have been described in the molecular 
weight distribution of CH]-fucose-Iabeled glycopeptides derived 
from psoriatic keratinocytes [1]. An increased constant for the 
association between the fucose-specific lectin, Uiex europeus 
agglu tinin, and isolated intact keratinocytes from psoriatic le-
sions [2] indicates that this abnormality involves the cell surface 
